View More
Expert review of safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.
Millie D. Long, MD, MPH, FACG, AGAF
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: August 24, 2021
Expired:
August 23, 2022
Review safety and efficacy data on new and emerging oral therapies for IBD, including S1PR modulators and JAK-STAT inhibitors.
Millie D. Long, MD, MPH, FACG, AGAF
Released: August 24, 2021
Clinical trials provide great opportunities for individual patients and the IBD community as a whole, but several barriers prevent optimal recruitment.
Millie D. Long, MD, MPH, FACG, AGAF
Released: August 17, 2021
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.